A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Phase 3 trial of seladelpar in PBC with inadequate response or unacceptable side effects with UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, seladelpar was well tolerated.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“As detailed earlier, pruritus was less frequent in seladelpar when compared to placebo.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“There were no reported treatment-related deaths [16,23,47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“However, ALT and GGT were significantly decreased with seladelpar which indicates reduced hepatocellular injury [47].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
In the citing paper
“Those on seladelpar 10 mg (n = 49) achieved −3.2 points while patients on placebo (n = 23) achieved −1.7 points (p = 0.005).”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [47]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationInterleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationAlternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Goforth, M. H., Subramanian, V., Mukundan, L., Ferrante, A. W., & Chawla, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.003 · Cited by 847
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citationCorpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Self-citationKuiper, E. M. M., Hansen, B. E., de Vries, R. A., den Ouden–Muller, J. W., van Ditzhuijsen, T. J. M., Haagsma, E. B., Houben, M. H. M. G., Witteman, B. J. M., van Erpecum, K. J., & van Buuren, H. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.003 · Cited by 460
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationKumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Self-citationCarbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Self-citationCorpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351
Self-citationEfficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2306185 · Cited by 314
Self-citationJacoby, A., Rannard, A., Buck, D., Bhala, N., Newton, J. L., James, O. F. W., & Jones, D. E. J. (2005) · Gut · doi:10.1136/gut.2005.065862 · Cited by 267
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Self-citationRecent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Self-citationHonda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Self-citationSchattenberg, J. M., Pares, A., Kowdley, K. V., Heneghan, M. A., Caldwell, S., Pratt, D., Bonder, A., Hirschfield, G. M., Levy, C., Vierling, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.013 · Cited by 191
Self-citationProtection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Reich, A., Riepe, C., Anastasiadou, Z., Mędrek, K., Augustin, M., Szepietowski, J. C., & Ständer, S. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2433 · Cited by 130
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
Self-citationHosonuma, K., Sato, K., Yamazaki, Y., Yanagisawa, M., Hashizume, H., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.20 · Cited by 123
Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
Oeda, S., Tanaka, K., Oshima, A., Matsumoto, Y., Sueoka, E., & Takahashi, H. (2020) · Diagnostics · doi:10.3390/diagnostics10110940 · Cited by 123
Hirschfield, G. M., Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., Manns, M. P., Parés, A., Spengler, U., Stiess, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.011 · Cited by 108
Self-citationHaczeyni, F., Wang, H., Barn, V., Mridha, A. R., Yeh, M. M., Haigh, W. G., Ioannou, G. N., Choi, Y., McWherter, C. A., Teoh, N. C. ‐., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1072 · Cited by 101
Self-citationFenofibrate for patients with asymptomatic primary biliary cirrhosis
Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H., & Yamamoto, K. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.894 · Cited by 99
Kremer, A. E., Mayo, M. J., Hirschfield, G. M., Levy, C., Bowlus, C. L., Jones, D. E., Steinberg, A. S., McWherter, C. A., & Choi, Y. (2021) · Liver International · doi:10.1111/liv.15039 · Cited by 97
Self-citationBowlus, C. L., Galambos, M. R., Aspinall, R. J., Hirschfield, G. M., Jones, D. E. J., Dörffel, Y., Gordon, S. C., Harrison, S. A., Kremer, A. E., Mayo, M. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.033 · Cited by 80
Self-citationVuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79
Self-citationGaloosian, A., Hanlon, C. L., Zhang, J., Holt, E. W., & Yimam, K. K. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00049 · Cited by 76
Xiao, H., Wang, Q., Liu, Y., Zheng Rui, Y. O. U., Zhao Lian, B. I. A. N., Qiu, D., & Ma, X. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2012.00574.x · Cited by 70
Kouno, T., Liu, X., Zhao, H., Kisseleva, T., Cable, E. E., & Schnabl, B. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102056 · Cited by 66
Transformation of 5-D itch scale and numerical rating scale in chronic hemodialysis patients
Lai, J.-W., Chen, H.-C., Chou, C.-Y., Yen, H.-R., Li, T.-C., Sun, M.-F., Chang, H.-H., Huang, C.-C., Tsai, F.-J., Tschen, J., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0475-z · Cited by 62
Xia, X., Jung, D., Webb, P., Zhang, A., Zhang, B., Li, L., Ayers, S. D., Gabbi, C., Ueno, Y., Gustafsson, J.-Å., et al. (2012) · Hepatology · doi:10.1002/hep.25919 · Cited by 54
Bojic, L. A., Burke, A. C., Chhoker, S. S., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Tirona, R. G., Yin, H., Pickering, J. G., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301830 · Cited by 52
Kamata, S., Honda, A., Ishikawa, R., Akahane, M., Fujita, A., Kaneko, C., Miyawaki, S., Habu, Y., Shiiyama, Y., Uchii, K., et al. (2023) · Antioxidants · doi:10.3390/antiox12081523 · Cited by 46
Takeuchi, Y., Ikeda, F., Fujioka, S., Takaki, T., Osawa, T., Yasunaka, T., Miyake, Y., Takaki, A., Iwasaki, Y., Kobashi, H., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06737.x · Cited by 41
Primary biliary cirrhosis in adults
Momah, N., & Lindor, K. D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.888950 · Cited by 35
Cited by
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
“98,99 The first RCT was the phase 3 study (ELATIVE) of elafibranor, a dual PPAR-α/δ agonist in which patients with an incomplete response to ursodeoxycholic acid were randomly assigned to receive elafibranor 80 mg (n=108) or placebo (n=53) while continuing ursodeo xycholic acid treatment.”
Self-citationFluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024
Du, Y., Bian, Y., Baecker, D., Dhawan, G., Semghouli, A., Kiss, L., Zhang, W., Sorochinsky, A. E., Soloshonok, V. A., & Han, J. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202500662 · Cited by 136
Trivedi, P. J., Hirschfield, G. M., Adams, D., & Vierling, J. M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.049 · Cited by 111
Self-citationBile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Assessment of fatigue and its impact in chronic liver disease
Younossi, Z. M., Kremer, A. E., Swain, M. G., Jones, D. E., Bowlus, C. L., Trauner, M., Henry, L. L., & Gerber, L. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.008 · Cited by 63
Self-citation
Metadata
- Authors
- Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., Zigmond, E., Jeong, S.-H., Yilmaz, Y., Kallis, Y., Corpechot, C., Buggisch, P., Invernizzi, P., Londoño Hurtado, M. C., Bergheanu, S., Yang, K., Choi, Y.-J., Crittenden, D. B., & McWherter, C. A.
- Affiliations
- University Health Network (CA)
- From the Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University Health Network, Toronto General Hospital, Toronto (G.M.H.); the Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento (C.L.B.), and CymaBay Therapeutics, Newark (K.Y., Y.-J.C., D.B.C., C.A.M.) — both in California; the University of Texas Southwestern Medical School, Dallas (M.J.M.), and the Departments of Medicine and Surgery, Baylor College of Medicine, Houston (J.M.V.) — both in Texas; the Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (A.E.K.); Liver Institute Northwest, Seattle (K.V.K.); the Division of Digestive Health and Liver Diseases, University of Miami, Miami (C.L.); the Liver Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires (A.V.); Centro de Investigación y Gastroenterología, Mexico City (A.L.L.G.C.); the Department of Basic Medical Sciences, Faculty of Publ...
- ORCID
- Hirschfield, Gideon M.
- Bowlus, Christopher L.
- Mayo, Marlyn J.
- Kremer, Andreas E.
- Vierling, John M.
- Kowdley, Kris V.
- Levy, Cynthia
- Villamil, Alejandra
- Janczewska, Ewa
- Zigmond, Ehud
- Jeong, Sook-Hyang
- Yilmaz, Yusuf
- Kallis, Yiannis
- Corpechot, Christophe
- Buggisch, Peter
- Invernizzi, Pietro
- Yang, Ke
- Choi, Yun-Jung
- Crittenden, Daria B.
- McWherter, Charles A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 783-794
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4392015136
- Cited by
- 286
- References
- 42
- Citations by year
- 2026: 106 · 2025: 128 · 2024: 52
- FWCI
- 73.92
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- CymaBay Therapeutics
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- seladelpar, primary biliary cirrhosis, PPARδ agonist, ursodeoxycholic acid, biochemical response, alkaline phosphatase, pruritus
- MeSH terms
- Acetates, Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.